Patients with moderate to severe allergic rhinitis (AR) often experience years of uncontrolled symptoms, worsened quality of ...

There’s no cure for allergies, but treatment can improve your quality of life ...

The perennial allergic rhinitis market is projected to progress steadily, supported by a relatively small but focused pipeline of emerging therapies. Companies developing candidates such as EBGLYSS ...

An update of recommendations for the treatment of seasonal allergic rhinitis (SAR) in adolescents and adults, issued by members of the Joint Task Force on Practice Parameters (JTFPP), changes initial ...

Please provide your email address to receive an email when new articles are posted on . Among patients with allergic rhinitis (AR), misdiagnosis and suboptimal therapeutic selection in the primary ...

Biopharmaceutical company Allovate has signed an agreement with personalized medicine firm Restore Health for the exclusive rights to provide Allerdent, a new therapeutic toothpaste delivery system ...

Please provide your email address to receive an email when new articles are posted on . Researchers called this the first study among children aged 1 to 4 years. The treatment group saw improved ...

Recent developments in allergen immunotherapy, improvements in primary care, and the emergence of a new treatment for other allergic conditions have improved the quality of care for seasonal allergies ...

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Rhinitis Market - A Global and Regional Analysis: Focus on Drug Type and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to ...

The "Allergic Rhinitis Market- A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The global ...

Oral second-generation antihistamines are considered first-line therapy for allergic rhinitis but are not indicated for nonallergic vasomotor rhinitis. 1 Intranasal antihistamines can also be ...

Adults with allergic rhinitis experience diagnostic delays and limited access to allergen immunotherapy, impacting quality of life and treatment satisfaction. ICE activity in Minnesota healthcare ...